|
Deferoxamine for the Treatment of Hemochromatosis Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Deferoxamine for the Treatment of Hemochromatosis conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Deferoxamine for the Treatment of Hemochromatosis Clinical research trials and Deferoxamine for the Treatment of Hemochromatosis healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Deferoxamine for the Treatment of Hemochromatosis. Deferoxamine for the Treatment of Hemochromatosis Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Deferoxamine for the Treatment of Hemochromatosis clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Deferoxamine for the Treatment of Hemochromatosis condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Deferoxamine for the Treatment of Hemochromatosis  Deferoxamine for the Treatment of Hemochromatosis
Deferoxamine for the Treatment of Hemochromatosis
For Condition: Diabetes Mellitus,Heart Disease,Hemochromatosis,Thalassemia
Status: No longer recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: When patients receive repeated blood transfusions the level of iron in the patient's blood can rise. When iron is processed in the body a protein known as hemosiderin can begin collecting in the organs. If too much hemosiderin collects in the organs they can begin to malfunction. This condition is called transfusional hemochromatosis. An organ of particular importance in transfusional hemochromatosis is the heart. Patients born with diseases requiring blood transfusions at birth begin to develop heart problems in their teens. These patients typically only live for 17 years. Adults that require transfusions can begin experiencing heart problems after 100-200 units of backed red blood cells. Deferoxamine (Desferal) is a drug that binds to iron and allows it to be excreted from the body. It is the only effective way to remove iron from patients who have been overloaded with iron because of multiple transfusions. Previous studies have lead researchers to believe that deferoxamine, when given as an injection under the skin (subcutaneous), can be delay or prevent heart complications. Researchers plan to continue studying patients receiving deferoxamine as treatment for the prevention of heart complications associated with repeated blood transfusions. In this study researchers will attempt; 1)To determine if deferoxamine, given regularly, can indefinitely prevent the heart, liver, and endocrine complications associated with transfusional hemochromatosis 2)To determine whether heart disease caused by transfusional hemochromatosis can be reversed by intensive treatment with deferoxamine.
Details: The purposes of this protocol are two-fold: 1) to determine whether deferoxamine, given subcutaneously on a regular basis, can indefinitely prevent the cardiac, endocrine and hepatic complications of transfusional hemochromatosis; and 2) to determine whether cardiac disease can be reversed by intensive intravenous treatment in patients who already have objective evidence of cardiac dysfunction. The clinical manifestations and course of patients who require regular blood transfusions is well established. Those with congenital anemias who require transfusions from birth develop cardiac disease in their teens and their mean of survival is only 17 years. Adults with acquired anemias begin to exhibit cardiac manifestations of iron deposition after 100-200 units of packed red cells. Deferoxamine, when given by the subcutaneous route, has been shown to reduce substantially the total iron burden in thalassemic patients. Our results indicate that cardiac complications are delayed or prevented. We plan to continue to follow our cohort of patients on optimal medical management to determine if chelation alters disease outcome. Patients with heavy iron burdens who already manifest cardiac disease will be chelated intensely to determine whether reducing the iron burden is associated with reversal of cardiac complications.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA Patients studied under this protocol will be at risk for or have evidence of significant excess tissue iron. Most patients will be on regular blood transfusion secondary to either congenital or acquired anemia. The majority of patients have homozygous beta thalassemia. Patients with sickle cell anemia will be included only when there is an absolute indication for regular blood transfusions (e.g., a history of stroke). Twenty to thirty adults with acquired anemia and good long-term prognosis will be accepted for study if chelation can be initiated early in their transfusion history (less than 30-50 units). EXCLUSION CRITERIA Such patients will be excluded from study if they have diabetes or cardiac disease due to another cause (coronary artery or valvular heart disease).
Total Enrollment: 165
Location and Contact Information:
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 850087; 85-H-0087
Study Start Date: April 22, 1985
Record last reviewed: January 20, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001203
Other Diabetes Mellitus Studies:
1. Incidence of Diabetes and Cardiovascular Disease in Mexican Americans
2. Nurses' Health Study
3. Assessing Continuous Glucose Monitors in Healthy Children
4. Consequences and Correlates of Weight Fluctuations
5. Tolerability of Three Local Anesthetic Formulations in Conjunction with NGX-4010 for the Treatment of Neuropathic Pain
Related Studies:
Other Diabetes Mellitus Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Deferoxamine for the Treatment of Hemochromatosis
|
|
|
|
|
|
|
|
